Sanofi is picking Innovent Biologics as its partner of choice in China for its top oncology candidates in a deal where Sanofi will take a €300 million ($307 million) equity stake in the biotech.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Medicenna closed public offering raising $20 million to advance its interleukin pipeline
DEALS AND FINANCINGS
Sanofi and Innovent entered collaboration to accelerate development of oncology medicines
Innovent gains China rights to tusamitamab ravtansine (SAR408701), an ADC against CEACAM5 that is in a global Phase 3 trial for second-line NSCLC, and joint development rights to Sanofi’s SAR444245, a recombinant IL-2 for various cancer indications, with the French pharma responsible for marketing the IL-2 in China. Subject to mutual agreement, Sanofi may also invest an additional €300 million in Innovent in the future.
Medicenna closed public offering raising $20 million to advance its pipeline
Medicenna announce the closing of marketed underwritten public offering at a price to the public of $1.50 per unit, for aggregate gross proceeds to the company of approximately $20 million. The Offering was made pursuant to an underwriting agreement entered into between Guggenheim Securities as sole book-running manager, and Bloom Burton Securities as co-manager. Medicenna plans to use the net proceeds of the offering primarily to fund the clinical development of MDNA11, the preclinical development of a BiSKIT candidate, working capital and for general corporate purposes.
